IDEAYA Biosciences Forms Clinical Collaboration with Roche for Pancreatic Cancer Drug
IDYA sits 38% above its 52-week low of $19.83.
Summary
IDEAYA Biosciences has partnered with Roche to evaluate its investigational PRMT5 inhibitor, IDE892, in combination with Roche's pan-RAS inhibitor for MTAP-deleted pancreatic cancer. This collaboration advances IDEAYA's pipeline in a high unmet need area.
Key Events · M&A and Partnerships · IDYA
-
Clinical Collaboration with Roche
IDEAYA Biosciences has entered into a clinical collaboration with F. Hoffmann-La Roche Ltd (Roche).
-
Combination Therapy for Pancreatic Cancer
The collaboration will evaluate IDEAYA's investigational PRMT5 inhibitor, IDE892, in combination with Roche's pan-RAS inhibitor, RG6505, for patients with MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma (PDAC).
-
IDEAYA to Sponsor Trial
IDEAYA will sponsor the clinical trial combination study, and Roche will supply RG6505.
-
Retained Commercial Rights
Both companies retain all commercial rights to their respective compounds, including as monotherapy and as combination therapies.
Analysis · IDYA · Life Sciences
This clinical collaboration with a major pharmaceutical company like Roche validates IDEAYA's PRMT5 inhibitor program and expands its pipeline into a challenging cancer indication. The combination therapy targets a specific genetic profile in pancreatic cancer, offering a new therapeutic approach where options are limited. IDEAYA sponsoring the trial while Roche supplies its drug is a favorable arrangement, allowing IDEAYA to leverage external resources for its development efforts. This partnership could significantly de-risk and accelerate the development of IDE892.
At the time of this filing, IDYA was trading at $27.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $19.83 to $39.28. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.